New fully-liquid pediatric hexavalent vaccine Vaxelis cleared in EU

The European Commission has granted the marketing authorization for Sanofi Pasteur MSD’s Vaxelis, a new fully-liquid hexavalent vaccine indicated for primary and booster vaccination of infants and toddlers from the age of sic weeks against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).

The approval of Vaxelis follows the positive opinion from the European Medicines Agency adopted on December 17, 2015.

"With Vaxelis Sanofi Pasteur MSD is proud to provide infants and toddlers with a new powerful tool that supports childhood immunization programs," said Stephen Lockhart, vice president of development at Sanofi Pasteur MSD, a joint venture of France’s Sanofi (Euronext: SAN) and US giant Merck & Co (NYSE: MRK).